Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 10/20 | 0.44 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.38 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | TK1 | P04183 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17358593 | 0.89 | KIF11 (0.43) | KIF11AHRSLC6A1SLC6A11KCNH2 | |
| SCHEMBL9508740 | 0.85 | KIF11 (0.49) | KIF11SLC6A1SLC6A11KCNH2TK1 | |
| SCHEMBL17357648 | 0.82 | KIF11 (0.42) | KIF11AHRSLC6A1SLC6A11KCNH2 | |
| SCHEMBL15281845 | 0.82 | KIF11 (0.49) | KIF11SLC6A1SLC6A11KCNH2TK1 | |
| SCHEMBL3490250 | 0.82 | KIF11 (0.49) | KIF11SLC6A1SLC6A11KCNH2TK1 | |
| SCHEMBL17359776 | 0.82 | PLA2G2A (0.39) | KIF11AHRSLC6A1SLC6A11KCNH2 | |
| SCHEMBL16214813 | 0.81 | KIF11 (0.50) | KIF11AHRSLC6A1SLC6A11KCNH2 | |
| SCHEMBL3487683 | 0.81 | KIF11 (0.50) | KIF11AHRSLC6A1SLC6A11KCNH2 | |
| SCHEMBL24937040 | 0.79 | LMNA (0.46) | KIF11SLC6A1SLC6A11KCNH2MEN1 | |
| SCHEMBL10434128 | 0.79 | LMNA (0.46) | KIF11SLC6A1SLC6A11KCNH2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150366888-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-12-24 | — | — | US | disclosed |
| US-20150366888-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366888-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, TYMP | KIF11 4078/4885AHR 3808/4885SLC6A1 3339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.